EARLY CLINICAL TRIALS OF IMAGING AGENTS Release Date: December 18, 2001 NOTICE: NOT-CA-02-010 National Cancer Institute The Biomedical Imaging Program (BIP), Division of Cancer Diagnosis and Treatment (DCTD), National Cancer Institute (NCI) plans to develop contracts to support Phase 1 (Safety) and Phase 2 (Preliminary Clinical Efficacy) clinical trials of promising imaging agents. These clinical trials will be used to rapidly evaluate the safety and diagnostic imaging capabilities of promising imaging probes, ligands, radiopharmaceuticals, and contrast agents that are of interest to NCI. The Safety and Preliminary Clinical Efficacy Imaging Clinical Trials contracts will create an infrastructure poised to rapidly evaluate molecularly-targeted imaging agents used to assess therapeutic anticancer agents on their molecular targets and determine clinically relevant correlates. The objectives of this program are: o to rapidly conduct clinical trials necessary to assess the safety of promising imaging agents; o to rapidly conduct clinical trials necessary to assess the diagnostic imaging capabilities and preliminary efficacy of promising imaging agents; o to characterize the molecular interactions of new molecular imaging agents with their targets through biopsies, assays, and other appropriate technologies and correlate those effects with clinically- relevant endpoints; o to develop new scientific insights into molecular pathways and determinants of the relationship of the targeted imaging agents to therapeutic drug response. Major emphasis shall be on imaging agents which are found to be safe and provide important structural, metabolic, or molecular imaging data which will be important and useful in the management of patients with cancer. These Phase 1 and Phase 2 clinical trials will obtain the necessary data to fulfill the Food and Drug Administration (FDA) criteria to eventually become an approved and potentially marketable imaging agent for specific imaging indications. The studies will explore promising imaging agents, and require rapid initiation, completion, and data reporting. These contracts will also require the ability to implement correlative studies validating the localization of the investigational imaging agents on their molecular target in tumors. Imaging agents may originate from investigators not affiliated with clinical sites. The detailed Request for Proposals (RFP: N01-CM-27018- 45) is available on the web site of the Research Contracts and Acquisition Branch, NCI at: http://rcb.nci.nih.gov/appl/rfp/published_rfps.jsp with instructions for submission of proposals and evaluation criteria. INQUIRIES For further information, contact: Kathleen Giuliano Contract Specialist Treatment, Biology, and Sciences Section, RCB Executive Plaza South 6120 Executive Blvd. Rockville, MD 20892-7220 e-mail: giulianok@mail.nih.gov voice: 301-496-8620 fax: 301-402-6699
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files. |